Abstract:The antisense fragment targeting the aberrant splice sites of the β‐thalassaemia allele, IVS‐2‐654 C→T (β654), pretranscript was cloned into the mammalian expression vector, pcDNA3. The recombinant construct, pCMVA, was then used to repair the defective splicing of the β654 mutant pretranscript in cultured β654 erythroid cells by the lipofectin‐mediated DNA transfection method. The total RNA was extracted at given time points after transfection and the effect of antisense RNA was studied by reverse transcription polymerase chain reaction (RT‐PCR)‐mediated mRNA quantitative assay, as well as globin chain microbiosynthesis. The antisense fragment transcribed from pCMVA effectively improved the β654 splicing pattern in cultured erythroid cells. The level of correctly spliced transcript increased from 0·19 (day 0 after transfection) to 0·58 (day 8) in β654/β654 homozygous erythroid cells, and from 0·45 (day 0) to 0·83 (day 8) in β654/βA heterozygous erythroid cells, as determined by the ratio of normally spliced β‐globin transcript over total β‐globin transcript. Correspondingly, the ratios of globin chain biosynthesis (β/α) increased from 0·16 (day 0) to 0·52 (day 8) in β654/β654 erythroid cells, and from 0·39 (day 0) to 0·84 (day 8) in β654/βA erythroid cells. Antisense RNA had no significant effect on the splicing pattern in βA/βA erythroid cells. The splicing pattern in transfected cells with pCMVA showed significant changes compared with that in untransfected cells and that in transfected cells with the control antisense fragment (human SRY gene sequence). In addition, we did not observe side‐effects on cytological features after the introduction of pCMVA. All these results indicated that the antisense RNA transcribed from the mammalian expression vector pCMVA could efficiently and specifically suppress the aberrant splicing pattern of β654 mutant pretranscript and restore the correct splicing pathway in vivo, leading to the improvement of globin chain biosynthesis in thalassaemic cells.

Treatment of β 654 -thalassaemia by TALENs in a mouse model.

Correction of RNA splicing defect in β<sup>654</sup>-thalassemia mice using CRISPR/Cas9 gene-editing technology

Correction of RNA splicing defect in β<sup>654</sup>-thalassemia mice using CRISPR/Cas9 gene-editing technology

Correction of RNA splicing defect in β654-thalassemia mice using CRISPR/Cas9 gene-editing technology.

Restoration of the Balanced Alpha/Beta-Globin Gene Expression in Beta(654)-Thalassemia Mice Using Combined Rnai and Antisense Rna Approach

Gene Editing of the Endogenous Cryptic 3' Splice Site Corrects the RNA Splicing Defect in the β654-Thalassemia Mouse Model

Amelioration of Β654-Thalassemia in Mouse Model with the Knockdown of Aberrantly Spliced Β-Globin Mrna

Correction of Β 654 -Thalassaemia Mice Using Direct Intravenous Injection of Sirna and Antisense RNA Vectors

Therapeutic Effects of Hematopoietic Stem Cell Derived From Gene-Edited Mice on β654-Thalassemia

Editing Aberrant Splice Sites Efficiently Restores Β-Globin Expression in Β-Thalassemia

A Novel Transgenic Mouse Model Produced from Lentiviral Germline Integration for the Study of Beta-Thalassemia Gene Therapy

Correction of Beta-Thalassemia IVS-II-654 Mutation in a Mouse Model Using Prime Editing

Restoration of correct βIVS2-654-globin mRNA splicing and HbA production by engineered U7 snRNA in β-thalassaemia/HbE erythroid cells

Construction of Antisense RNA Expression Vectors and Correction of Splicing Defect in Human Β-Globin Gene (IVS-2-654 C→T Mutant) in HeLa Cells

Reversal of Aberrant Splicing of Beta-Thalassaemia Allele (Ivs-2-654 C -> T) by Antisense Rna Expression Vector in Cultured Human Erythroid Cells

A Transgenic Mouse Model for Dna/Rna Gene Therapy of Human Beta Thalassemia

Gene replacement of α-globin with β-globin restores hemoglobin balance in β-thalassemia-derived hematopoietic stem and progenitor cells

In situ correction of various β-thalassemia mutations in human hematopoietic stem cells

CRISPR/Cas-based gene editing in therapeutic strategies for beta-thalassemia

Optimized TAL effector nucleases (TALENs) for use in treatment of sickle cell disease.

β-Thalassemia gene editing therapy: Advancements and difficulties

Treatment of β 654 -thalassaemia by TALENs in a mouse model.

Correction of RNA splicing defect in β&lt;sup&gt;654&lt;/sup&gt;-thalassemia mice using CRISPR/Cas9 gene-editing technology

Correction of RNA splicing defect in β<sup>654</sup>-thalassemia mice using CRISPR/Cas9 gene-editing technology

Correction of RNA splicing defect in β654-thalassemia mice using CRISPR/Cas9 gene-editing technology.

Restoration of the Balanced Alpha/Beta-Globin Gene Expression in Beta(654)-Thalassemia Mice Using Combined Rnai and Antisense Rna Approach

Gene Editing of the Endogenous Cryptic 3' Splice Site Corrects the RNA Splicing Defect in the β654-Thalassemia Mouse Model

Amelioration of Β654-Thalassemia in Mouse Model with the Knockdown of Aberrantly Spliced Β-Globin Mrna

Correction of Β 654 -Thalassaemia Mice Using Direct Intravenous Injection of Sirna and Antisense RNA Vectors

Therapeutic Effects of Hematopoietic Stem Cell Derived From Gene-Edited Mice on β654-Thalassemia

Editing Aberrant Splice Sites Efficiently Restores Β-Globin Expression in Β-Thalassemia

A Novel Transgenic Mouse Model Produced from Lentiviral Germline Integration for the Study of Beta-Thalassemia Gene Therapy

Correction of Beta-Thalassemia IVS-II-654 Mutation in a Mouse Model Using Prime Editing

Restoration of correct βIVS2-654-globin mRNA splicing and HbA production by engineered U7 snRNA in β-thalassaemia/HbE erythroid cells

Construction of Antisense RNA Expression Vectors and Correction of Splicing Defect in Human Β-Globin Gene (IVS-2-654 C→T Mutant) in HeLa Cells

Reversal of Aberrant Splicing of Beta-Thalassaemia Allele (Ivs-2-654 C -> T) by Antisense Rna Expression Vector in Cultured Human Erythroid Cells

A Transgenic Mouse Model for Dna/Rna Gene Therapy of Human Beta Thalassemia

Gene replacement of α-globin with β-globin restores hemoglobin balance in β-thalassemia-derived hematopoietic stem and progenitor cells

In situ correction of various β-thalassemia mutations in human hematopoietic stem cells

CRISPR/Cas-based gene editing in therapeutic strategies for beta-thalassemia

Optimized TAL effector nucleases (TALENs) for use in treatment of sickle cell disease.

β-Thalassemia gene editing therapy: Advancements and difficulties

Correction of RNA splicing defect in β<sup>654</sup>-thalassemia mice using CRISPR/Cas9 gene-editing technology